Mayzent is owned by Novartis.
Mayzent contains Siponimod Fumaric Acid.
Mayzent has a total of 2 drug patents out of which 0 drug patents have expired.
Mayzent was authorised for market use on 26 March, 2019.
Mayzent is available in tablet;oral dosage forms.
Mayzent can be used as a method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose.
Drug patent challenges can be filed against Mayzent from 2023-03-27.
The generics of Mayzent are possible to be released after 30 November, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.|
|US7939519||NOVARTIS||Immunosuppresant compounds and compositions|| |
(5 years from now)
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8492441||NOVARTIS||Dosage regimen of an S1P receptor agonist|| |
(7 years from now)
|New Chemical Entity Exclusivity (NCE)||Mar 26, 2024|
|M (M)||Mar 1, 2025|
Drugs and Companies using SIPONIMOD FUMARIC ACID ingredient
NCE-1 date: 2023-03-27
Market Authorisation Date: 26 March, 2019
Treatment: A method of treating multiple sclerosis by administering siponimod using a titration scheme to reach a maintenance dose
Taiwan, Province of China
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic